David Anderson
Direttore/Membro del Consiglio presso Halsa Pharmaceuticals, Inc.
Profilo
David Anderson is currently a Director at Halsa Pharmaceuticals, Inc. He was previously the Chairman, President & Chief Executive Officer at MithraGen, Inc. from 2001 to 2009, Chairman at PLx Pharma, Inc., Chairman at Nanospectra Biosciences, Inc., and Chief Operating Officer at Tanox, Inc. from 1987 to 2013.
Mr. Anderson received a graduate degree from the University of Houston in 1976 and an undergraduate degree from the same institution.
Posizioni attive di David Anderson
| Società | Posizione | Inizio |
|---|---|---|
| Halsa Pharmaceuticals, Inc. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di David Anderson
| Società | Posizione | Fine |
|---|---|---|
MithraGen, Inc.
 MithraGen, Inc. Pharmaceuticals: MajorHealth Technology MithraGen, Inc. develops immunotherapies for the treatment and prevention of cancer and infectious diseases. The company was founded in 2000 and is headquartered in Houston, TX. | Presidente | 01/01/2009 |
PLx Pharma, Inc. /Old/
 PLx Pharma, Inc. /Old/ Pharmaceuticals: OtherHealth Technology PLx Pharma, Inc. engages in the development of formulations of non steroidal anti-inflammatory drugs. Its products include GI-safer NSAID technology and product pipeline; aspirin, ibuprofen and indomethacin as well as other drugs for over-the-counter and prescription markets using the PLxGuard technology. The company was founded in 2003 and is headquartered in Houston, TX. | Presidente | 24/08/2011 |
Tanox, Inc.
 Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | Direttore operativo | - |
Nanospectra Biosciences, Inc.
 Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX. | Presidente | - |
Formazione di David Anderson
| University of Houston | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 5 |
|---|---|
Nanospectra Biosciences, Inc.
Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX. | Health Technology |
PLx Pharma, Inc. /Old/
PLx Pharma, Inc. /Old/ Pharmaceuticals: OtherHealth Technology PLx Pharma, Inc. engages in the development of formulations of non steroidal anti-inflammatory drugs. Its products include GI-safer NSAID technology and product pipeline; aspirin, ibuprofen and indomethacin as well as other drugs for over-the-counter and prescription markets using the PLxGuard technology. The company was founded in 2003 and is headquartered in Houston, TX. | Health Technology |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | Health Technology |
MithraGen, Inc.
MithraGen, Inc. Pharmaceuticals: MajorHealth Technology MithraGen, Inc. develops immunotherapies for the treatment and prevention of cancer and infectious diseases. The company was founded in 2000 and is headquartered in Houston, TX. | Health Technology |
| Halsa Pharmaceuticals, Inc. |
- Borsa valori
- Insiders
- David Anderson
